Theratechnologies Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy THTX

*Your capital is at risk

$3.39

+0 (+0%)

At Close: Dec 24, 2025

Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional Cancers

07:00am, Tuesday, 08'th Dec 2020

I n addition to ovarian and triple-negative breast cancers , TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers

Theratechnologies to Present at the Piper Sandler Virtual Healthcare Conference

04:01pm, Monday, 23'rd Nov 2020

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat

Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH

10:31am, Monday, 16'th Nov 2020

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat

Theratechnologies Announces that Data on the Mechanism of Effect of Tesamorelin in NAFLD will be Presented at The Liver Meeting® 2020

01:36pm, Friday, 06'th Nov 2020

MONTREAL, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat

Theratechnologies Announces Departure of Chief Commercial Officer

04:01pm, Tuesday, 03'rd Nov 2020

MONTREAL, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by